John G. Kuruvilla

John G. Kuruvilla

Toronto, ON M5G2M9, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 216 publications

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: June 15, 2026

First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.

First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.

Journal: Current oncology (Toronto, Ont.)

Published: May 25, 2026

Targeted therapy in early-stage classical Hodgkin lymphoma.

Targeted therapy in early-stage classical Hodgkin lymphoma.

Journal: Blood

Published: April 09, 2026

Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.

Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.

Journal: Leukemia & lymphoma

Published: February 25, 2026

Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? - the PRO.

Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? - the PRO.

Journal: Haematologica

Published: January 21, 2026

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Journal: Blood neoplasia

Published: January 09, 2026

Management of relapsed/refractory DLBCL in the era of novel agents and new approaches.

Management of relapsed/refractory DLBCL in the era of novel agents and new approaches.

Journal: Leukemia & lymphoma

Published: January 05, 2026

End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study.

End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study.

Journal: British journal of haematology

Published: December 29, 2025

Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada.

Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada.

Journal: Current oncology (Toronto, Ont.)

Published: December 17, 2025

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.

Journal: Future oncology (London, England)

Published: December 10, 2025

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

Journal: American journal of hematology

Published: November 21, 2025

Diffuse large B-cell lymphoma: what clinical progress have we seen in the last 5 years?

Diffuse large B-cell lymphoma: what clinical progress have we seen in the last 5 years?

Journal: Expert opinion on investigational drugs

Published: November 08, 2025

Showing 1-12 of 216

Last Updated: 09/26/2026